Clinical Trial Update: Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy [Phase 2]

View source ↗

Summary

Phase II trial update for HM781-36B in metastatic/recurrent head and neck squamous cell carcinoma after platinum therapy failure or ineligibility.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• HM781-36B (HM781-36B)

Snippet

Sponsor: Yonsei University | Conditions: HNSCC | Phase 2 | Status: UNKNOWN